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S_ry Clinical data were reviewed in 325 patients with prostatic adenocarcinoma followed up for a mean
of 13 years. Paraffin-embedded tumour biopsy specimens from the primary tumours were available for flow
cytometry (FCM) in 273 cases. Intra-tumour heterogeneity in DNA index (DI) was found in 4% of the
tumours (54 cases were analysed). S-phase fraction (SPF) and DNA ploidy were significantly interrelated.
Aneuploidy and high SPF were significantly related to both a high T category and high Gleason score. The
progression in TI -2M0 tumours was related to Gleason score (P= 0.009), DNA ploidy (P = 0.006) and SPF
(P= 0.007), while the Gleason score (P= 0.0013), DNA ploidy (P 0.002) and SPF (P<0.001) had prognos-
tic value in univariate survival analysis. In the entire cohort, the T category (P<0.001), M category
(P<0.001), Gleason score (P<0.001), DNA ploidy (P<0.001) and SPF (P<0.001) were significant prognos-
tic factors. In Cox's analysis, the M category (P<0.001), Gleason score (P<0.001), T category (P = 0.003),
age (P=0.001) and SPF (P=0.087) were independently related to prognosis. In the TI-2MO tumours,
Gleason score (P<0.001), T category (P = 0.022) and SPF (P = 0.058) were independent predictors. A novel
classification system in which the DNA ploidy or SPF and the Gleason score were combined was found to be
of significant prognostic value in all MO tumours (P<0.001). The results suggest that FCM can be used as an
adjunct to conventional histological assessments for determination of the correct prognostic category in
prostatic adenocarcinoma.
Prostatic adenocarcinoma is the most common malignancy
among elderly men, although only a small fraction of the
tumours progress to metastatic disease. The latent cancer is
3-8 times more common than the clinical form of the
disease. Accordingly, identification of the malignant subset of
prostatic tumours would be of great help in planning treat-
ment and follow-up strategies for the ever-increasing number
of men suffering from this age-related disease (Muir et al.,
1991). Currently, the prognostic evaluation of prostatic
adenocarcinoma is based on tumour staging (UICC, 1978)
and on subjective histological grading. Currently, there are
several different grading systems for prostatic adenocar-
cinoma, and most correlate with prognosis (Mostofi, 1975;
Gleason 1977; Gaeta et al., 1980). DNA flow cytometry
(FCM) provides more objetive prognostic information than
grading in several human tumours (Frierson, 1991; Deitch &
DeVere White 1992; Lipponen et al., 1993) and measurement
of the S-phase fraction (SPF) has given prognostic estimates
superior to DNA ploidy alone (Frierson, 1991; Visakorpi et
al., 1991; Lipponen et al., 1993). From previous studies we
know that DNA ploidy correlates with the histological grade
in prostatic adenocarcinoma (Badalament et al., 1991;
Eskelinen et al., 1991; Robertson & Paulson 1991; Visakorpi
et al., 1991; Di Silvero et al., 1992), while the independent
prognostic value of DNA flow cytometric data is controver-
sial. Several studies have shown that aneuploidy carries a
greater risk for tumour progression and a more unfavourable
prognosis than diploidy (Stephenson et al., 1987; Adolfsson
& Tribukait, 1991; Badalament et al., 1991; Visakorpi et al.,
1991; Wirth et al., 1991; Zetterberg & Forsslund, 1991;
Deitch & DeVere White, 1992; Di Silvero et al., 1992; Peters-
Gee et al., 1992; Song et al., 1992). The behaviour of
moderately differentiated tumours is difficult to predict. Some
of them progress slowly, whereas others have a rapid pro-
gression. It is assumed that the aneuploid cell lines (Nagel &
Al-Abadi, 1991) in the intermediate tumour group are res-
ponsible for the accelerated progression in these tumours. It
is thus important to identify those tumours that are more
aggressive, and studies of ploidy may add useful prognostic
information. In particular, the prognostic value of the flow
cytometric SPF is incompletely evaluated at present in pros-
tatic adenocarcinoma (Shankey et al., 1993). The flow
cytometric assessment of prognostic factors is complicated by
the intra-tumour variation in DNA indices (DI) (Kallioniemi,
1988; Carey et al., 1990; Lipponen et al., 1993), including
prostatic adenocarcinoma (Nagel & Al-Abadi, 1991). The
present study was designed to evaluate the prognostic value
of DNA ploidy and SPF in relation to Gleason score and
clinical stage in a cohort of 273 patients followed up for over
13 years at one university hospital. In addition, the impact of




The 325 patients with prostatic adenocarcinoma were diag-
nosed, treated and followed up between 1971 and 1992 at
Kuopio University Hospital in Finland. Archival paraffin-
embedded tumour samples from 273 of the patients were
suitable for FCM, and these patients are separately analysed
in this study. The age of the patients at diagnosis was
71.5 ± 7.1 (mean ± s.d.) years (range-39-92), and the follow-
up period lasted 13.0 ± 3.3 (mean ± s.d.) years (range
7.5-21.4). Diagnosis, clinical staging (UICC, 1978), treat-
ment and follow-up were carried out mainly by two
urologists according to standard practice. During the first 5
years of follow-up the examinations were done every 3-6
months, and thereafter approximately once per year. This
scheme was modified if necessary because of the activity of
the disease. The tumours were treated as curatively as pos-
sible according to generally accepted principles. Eight
patients underwent radical prostatectomy, four received
radical radiation therapy, 107 were treated by oestrogen and
four were treated with oestramucine phosphate. Orchiectomy
was performed in 159 patients and transurethral resection in
85 patients. One hundred and six patients were subjected to
active follow-up only without any primary therapy. There
were 101 (114) T1, 64 (77) T2, 82 (101) T3 and 26 (33) T4
patients. The number in brackets indicates the number of
cases in the original cohort. One hundred and eighty-nine of
the patients included in FCM analysis had no detectable
metastases at the time of diagnosis, while 84 had metastatic
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disease. The progression of tumours was defined as an in-
crease in T or M category during the follow-up period. The
N category was not used because it can be accurately defined
only by pelvic lymph node dissection, which is seldom per-
formed in Scandinavia. The cause of death was verified from
the patient files, death certificates and from the Finnish
Cancer Registry.
F7ow cytometry
The paraffin-embedded samples (273 samples) used for FCM
consisted of Tru-cut needle biopsies, transurethral resection
specimens and open surgical biopsies from the primary
tumours fixed in 10% buffered formalin (pH 7.0). There were
85 Tru-cut biopsy specimens, and in 188 cases transurethral
resection or surgical biopsy specimens were available. The
mean number of Tru-cut biopsy specimens per tumour was 4
(range 2-6), and they contained mainly cancer tissue since
Tru-cut biopsy specimens were usually taken from prostates
that were considered to be malignant on the basis of clinical
examination. The histopathological samples were taken
before any treatment was administered. The presence of pros-
tatic adenocarcinoma was ascertained by light microscopy of
5 gm sections adjacent to the 100 jm sections cut for flow
cytometry. In 54 randomly chosen cases, 3-5 samples were
examined from the same tumour to detect intra-tumour
heterogeneity of DNA indices. Samples were prepared using
a standard method previously described (Lipponen et al.,
1993). In brief, 100-pm-thick sections were treated with
g ml-' proteinase K (Sigma, St Louis, MO, USA) for
30 mm at room temperature. After infiltration, the nuclei
were treated with lOpgmV-' RNAse and stained with
25g.gml-' ethidium bromide (Sigma) for at least I h. The
DNA was determined by FCM (FACScan, Becton Dickin-
son, Mountain View, CA, USA) using an emission at 488 nm
at 200 mW. The total emission above 560 nm was recorded.
As the staining intensity of fixed nucli varies from one
sample to another, no internal standard was added. The
lowest peak was given a DNA index (DI) value of 1.00, and
the DIs of other peaks were calculated using this as a
reference. The histograms were interpreted by one of us
(S.N.) without knowledge of the clinical outcome. The SPF
could be caculated either using the Ceilfit program of the
FACScan flow cytometer or manually by a modified recti-
linear method (Baisch et al., 1975; Camplejohn et al., 1989)
in 264/273 (97%) of the tumours. If the automatic and the
manual methods gave different results, the lower SPF was
chosen. The measurement of SPF was based on Tru-cut
biopsy specimens in 81 cases (81/264, 30%). Tumours with a
DI of 1.00 were designated diploid, and those with a DI
> 1.00 were considered aneuploid. Tumours with a DI
between 1.90 and 2.10 were considered tetraploid. If there
were several aneuploid stem lines, the tumours were classified
as multiploid. In tumours in which the DNA analysis showed
heterogeneity, the aneuploid DI value and corresponding
SPF values were used in further analyses. The coefficint of
variation (CV) was 4.4 ± 1.5% (mean ± s.d.). The CVs of
Tru-cut biopsy specimens and surgical or transurethral
biopsy specimens were 4.5 ± 1.6% and 4.3 ± 1.5% respec-
tively.
Histological grading
The histological grading of tumours was done according to
the Gleason (1977) grading system. The samples were
evaluated by one investigator who was unaware of the
clinical data. The grading of 116 (116/325, 35%) tumours
was based on Tru-cut biopsy specimens, and a mean of four
Tru-cut biopsy specimens per tumour were available (range
2-6). The Tru-cut biopsy specimens contained mainly cancer
tissue since Tru-cut biopsy specimens were taken from
tumours that were already considered malignant on the basis
of clinical examination. Accordingly, the grading of the
tmours could be based on representative samples in all
cases. The Gleason scores were 2-4 in 12 (18), 5-7 in 127
(149) and 8-10 in 134 (158) tumours. (The numbers in
brackets indicate the number of cases in the original cohort.)
Statistical methods
The basic statistical calculations were done using the SPSS-X
program package on an IBM computer. The statistical tests
used are indicated in the results when appropriate. Frequency
distributions were tested by the chi-square test and Yates'
correction was applied when necessary. The differences
between the means of continuous variables were tested by
analysis of variance. The univariate survival analysis (log-
rank analysis, SPSS-X) was based on the life-table method
with the statistics by Lee and Desu (1972). A multivariate
survival analysis was done with the BMDP (2L) (Cox, 1972)
in a stepwise manner and continuous variables were used as
absolute numbers in this analysis. The enter limit was
P<0.1, the remove limit was P>0.15 and deaths due to
prostatic adenocarcinoma were used as events. The grouping
of tumours according to their SPF was based on tertiles and
on the median value. The multivariate analysis included only
cases in which a complete set of data was available (FCM
was not available in all cases). The year of treatment and
patient age were included in the multivariate analysis to
control their possible confounding effect on the results of
biological variables. Univariate survival curves for T category
and Gleason score are shown for the entire cohort (325
patients).
Redts
The FCM analysis showed that 158 of the 273 tumours
(58%) were diploid and 115 (42%) aneuploid (non-diploid).
Of the latter, 41 were tetraploid, three multiploid and 71
were non-tetraploid aneuploid. There were 297 diploid and
193 aneuploid tumour samples (in 54 tumours 3-5 samples
were analysed). The SPF could not be calculated in four of
the diploid and 12 of the aneuploid tumours. In the diploid
tumours the SPF ranged from 0.2 to 18.9%, mean 4.0 ± 2.0
(s.d.), and in the aneuploid tumours from 1.6 to 31.9%,
mean 11.8 ± 5.7 (s.d.). Thus, the mean SPF was nearly three
times higher in the aneuploid tumours than in the diploid
tumours. The mean (s.e.) SPF in Tru-cut biopsy specimens
(n = 81) was 6.7% (0.6%), and in surgical or transurethral
biopsy (n = 182) 7.3% (0.4%) (t-test; t = 0.87,
P = 0.38).
The relationship between T category, M category, Gleason
score and DNA ploidy is shown in Table I. There were 165
TI-2M0-1 tumours, i.e. localised tumours with or without
evidence of metastasis. Of these, 119 (72%) were diploid,
whereas of the 108 T3-4M0-1, i.e. locally infiltrating
tumours with or without metastases, only 39 (36%) were
diploid. Eighty-four of the patients had distant metastases,
and in only 26 (31%) of these patients were tumours diploid.
The Gleason score was signicnly related to DNA aneu-
ploidy, as shown in Table I. Diploid tumours were more
common (8/12, 67%) among tumours with a Gleason score
Tabek I The relationship between cinical stage, Gkason score and
DNA ploidy
Diploid Aneuploid
Variable Number (%) (%) X2, P
Ti 101 84 16 50.3, P<0.0001
T2 64 53 47
T3 82 36 64
T4 26 35 65
MO 189 70 30 36.1, P<0.0001
Ml 84 31 69
Gleason 2-4 12 67 33 41.4, P<0.0001
Gleason 5-7 127 78 22
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of 2-4, while aneuploidy was found in the majority of
tumours (82/134, 61%) with Gleason scores of 8-10.
Intra-tumour heterogeneity of DI was found in only 2 of
the 54 tumours (4%). There was also relatively little variation
in SPF since the variation in 54 tumours from which multiple
samples had been taken was 3.3 ± 3.4% (mean ± s.d.), which
corresponds to a mean variation of 1.9% within each multi-
ple sample.
SPF was significantly related to T and M categories so that
T3-4 tumours and tumours with distant metastasis had high
SPFs. Tumours with high Gleason scores also had a high
SPF (Table II). DNA ploidy and SPF were independent of
patient age (P>0.5).
In univariate survival analysis, T category (Figure 1), M
category (X2= 107.6, P<0.0001), Gleason score (Figure 2),
DNA ploidy (Figure 3) and SPF (Figure 4) were significnt
indicators of long-term prognosis. There was no significant
difference (X2 = 0.2, P = 0.6) in the 10 year survival between
tetraploid (10 year survival 30%) and non-tetraploid aneu-
ploid tumours (10 year survival 20%). Progression of
Tl-2M0 tumours during the follow-up was significantly
related to Gleason score, DNA ploidy and SPF (Table III).
In the survival analysis of Tl-2M0 tumours, Gleason score
(X2 = 13.4, P= 0.0013), DNA ploidy (Figure 5) and SPF
(Figure 6) were significantly related to prognosis. In patients
with diploid TIMO tumours (n = 84) the 10 year survival was
85%, in contrast to 65% in patients with aneuploid tumours
(n = 14) (X2= 4.8, P = 0.026). The SPF showed a non-
significant trend (X2=2.3, P=0.12).
Table H The S-phase fraction in various
adenocarcioma
Tumours with a Gleason score of 5-7 could be separated
into two prognostic groups on the basis of DNA ploidy
(x2=4.0, P=0.0439) and median SPF (5%) (X2= 11.5,
P = 0.0007). In patients with Ti-2MO tumours with Gleason
score 5-7, the 10 year survival was 90% in those with
diploid tumours (n = 84), and 45% in those with aneuploid
tumours (n = 18, x2 = 14.9, P = 0.0001). The survival of
patients with an SPF below the median value of 5% (n = 72)
was 90%, and of those with an SPF above the median
(n = 28) was only 50% (,e = 14.4, P= 0.0001).
We defined a two-category system for prostatic adenocar-
cinoma in which Gleason score 2-4 and Gleason score 5-7
tumours with a diploid DNA histogram or SPF lower than
5% were combined into category A(1). Gleason score 8-10
tumours and the rest of Gleason score 5-7 tumours with
aneuploid DI or an SPF above the median were combined
into category A(2). The results of a survival analysis using
this system (Table IV) indicate that this new classification is a
highly significant prognostic factor.
The results of multivariate survival analysis in the entire
cohort, in Tl-4M0, in Tl-2M0 and in TIMO tumours are
shown in Table V. If the Gleason score was not included in
the analysis, the independent predictors were as shown in
Table VI. If the new prognostic category (A) was included in
the multivariate survival analyses, it included all the available
100
801 subgroups of prostatic
Variable Number SPF (s.e.)% F/li', P
T1 97 5.32 (0.42) 6.9, P<0.0001
T2 63 6.26 (0.70)
T3 79 9.18 (0.69)
T4 25 9.14 (1.45)
MO 184 6.25 (0.40) - 3.83', P = 0.0005
Ml 80 9.13 (0.65)
Gkason 2-4 11 7.49 (1.93) 28.6, P<0.0001
Gleason 5-7 123 4.97 (0.36)
Gleason 8-10 130 9.17 (0.55)
Diploid 156 3.94 (0.17) 54.2, P<0.0001
Non-tetraploid 66 11.94 (0.81)
aneuploid
Tetraploid 38 11.63 (0.78)
Multiploid 3 12.30 (4.53)
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Fugwe 1 Survival of patients subdivided according to T
category. The difference between the curves is significant
(X2=92.1, P<0.0001). Curve A, T1, n= 114; curve B, T2,







40 80 120 160 200
Follow-up time (months)
Fiwe 2 Survival of patients subdivided according to Gkason
score. The difference in survival is significant (x2 = 50.1,
P<0.0001). Curve A, Gkason score 2-4, n = 18; curve B,
Gleason score 5-7, n = 149; curve C, Gleason score 8-10,
n= 158.
40 80 120 160 200
Follow-up time (months)
F "e 3 Survival of patients subdivided according to DNA
ploidy. The difference between the curves is significnt (2 = 31.0,
P<0.0001). Curve A, diploid, n = 158; curve B, aneuploid,
n= 115.312 S. VESALAINEN et al.
prognostic information in addition to T and M categories
(Table VII).
In patients treated by oestrogens and orchiectomy indepen-
dent predictors were M category (P<0.001), Gleason score
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Follow-up time (months)
Fugwe 4 Survival of the patients subdivided according to SPF.
The difference in survival among the curves is significant
(X2 = 35.3, P<0.0001). Curve A, SPF <3.9%, n = 89; curve B,








40 80 120 160 200
Follow-up time (months)
Fugwe 5 Survival of patients with a TI-2M0 tumour sub-
divided according to DNA ploidy. The difference in survival is
significant (12= 9.5, P<0.002). Curve A, diploid, n = 112; curve










Fgwe 6 Survival of patients with a TI-2M0 tumour sub-
divided according to median value of the SPF. The difference
between the curves is significant (X2= 12.1, P<0.0005). Curve A,
SPF <5%, n =90{, curve B, SPF >5%, n = 57.
(P= 0.066), but if the Gleason score was not used in the
analysis SPF was included among the independent predictors
(P = 0.07). In patients treated by transurethral resection M
category (P<0.001), patient age (P = 0.021) and T category
(P= 0.038) had independent prognostic value. In those
patients subjected to active surveillance, T category
(P = 0.002) and DNA ploidy (P = 0.02) were independent
prognostic factors. If all the types of therapy were entered in
multivariate analysis as binary data (yes/no), oestrogen
therapy (P = 0.051) and orchiectomy (P = 0.059) resulted in
TabIkm The progression of TI -2MO tumours in relationship to
Gkason score, DNA ploidy and SPF
No.
progression Progression X, P
Variable Number (%) (%)
Gleason 2-4 14 86 14 9.42, P=0.009
Gleason 5-7 114 81 19
Gkason 8-10 39 59 35
Diploid 107 86 14 7.50, P = 0.006
Aneuploid 34 65 35
SPF <3.9% 62 87 13 9.7, P =0.007
SPF 3.9-6.6% 49 84 16
SPF >6.6% 27 59 41
Table IV Survival of prostatic adenocarcinoma subdivided
according to category Al and A2'
Alive at Alive at
5 years 10 years
Number (%P (%) X2 P
All cases
Category A= 1 139 85 75
Category A=2 186 50 25 41.5, P<0.0001
T3-4MO-l
Category A = 1 21 45 20 0.1, P = 0.7
Category A=2 113 35 15
TJ-4MO
Category A = 1 119 90 85
Category A=2 105 70 45 24.4, P<0.0001
Tl-2MO
Category A = I 110 95 90
Category A=2 64 75 50 21.9, P<0.0001
'Category A is I if Gleason score is 2-4 or score 5-7 tumour is
diploid. Category A is 2 if Gleason score is 8-10 or score 5-7
tumour is aneuploid. The results are similar if SPF 5% is used as a
cut-off limit.
Table V Results of the multivariate survival analysis with Gleason
score included
Hazard rate
p(s.e.) P-value (95% CI)
All cases
M category 1.096 (0.240) <0.001 2.99 (1.85-4.83)
Gleason score 0.710 (0.229) <0.001 2.03 (1.29-3.21)
T category 0.478 (0.134) 0.003 1.61 (1.23-2.11)
Age 0.042 (0.012) 0.001 1.04 (1.02-1.07)
SPF 0.024 (0.013) 0.087 1.02 (1.00-1.05)
Ti-4MO
T category 0.777 (0.174) <0.001 2.17 (1.53-3.08)
Age 0.057 (0.018) 0.001 1.06 (1.02-1.10)
Gleason score 0.925 (0.331) 0.004 2.52 (1.30-4.89)
Ti-2MO
Gleason score 0.791 (0.396) <0.001 2.20 (1.00-4.87)
T category 0.969 (0.405) 0.022 2.64 (1.17-5.92)
SPF 0.069 (0.033) 0.058 1.07 (1.00-1.14)
TIMO
Gleason score 1.613 (0.587) 0.008 5.02 (1.55-16.23)
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Table VI Results of the multivariate survival analysis with Gleason
score excluded
Hazard rate
p (s.e.) P-value (95% CI)
All cases
M category 1.096 (0.238) <0.001 2.99 (1.85-4.81)
T category 0.646 (0.124) <0.001 1.90 (1.48-2.44)
Age 0.042 (0.013) 0.002 1.04 (1.01-1.07)
SPF 0.030 (0.013) 0.031 1.03 (1.00-1.06)
Ti-4MO
T category 0.969 (0.159) <0.001 2.63 (1.91 -3.62)
Age 0.056 (0.019) 0.001 1.05 (1.02-1.09)
DNA ploidy 0.529 (0.306) 0.086 1.69 (0.92-3.12)
Ti-2MO
T category 1.253 (0.384) 0.001 3.50 (1.62-7.54)
SPF 0.086 (0.028) 0.006 1.09 (1.03-1.15)
TIMO
DNA ploidy 1.730 (0.643) 0.015 5.64 (1.58-20.0)
Hazard rate = e'; Cl, confidence interval.
Table VII Results of the multivariate survival analysis when the
novel prognostic category (A = I or 2)a is included
Hazard rate
l( s.e.) P-value (95% CI)
All cases
M category 1.222 (0.238) <0.001 3.39 (2.11-5.46)
Category A 1.104 (0.295) <0.001 3.02 (1.67-5.44)
T category 0.361 (0.133) 0.008 1.43 (1.10-1.87)
Ti-4MO
Category A 1.569 (0.404) <0.001 4.80 (2.14-10.77)
T category 0.515 (0.156) 0.001 1.67 (1.22-2.29)
Ti-2MO
Category A 2.167 (0.462) <0.001 8.73 (3.46-21.99)
TJMO
Category A 2.504 (0.680) <0.001 12.23 (3.27-45.78)
aSee the footnote in Table IV.
lowered survival probability, while other types of therapy
had no independent prognostic significance.
Heterogeneity of DNA indices is a common feature of malig-
nant neoplasms. The fraction of tumours showing hetero-
geneous DNA indices in FCM vanres usually between 20%
and 40% (Kallioniemi, 1988; Lipponen et al., 1993), although
up to 90% of lung tumours may show heterogeneous DNA
indices (Carey et al., 1990). A high proportion of prostatic
adenocarcinomas have been reported to have heterogeneous
DNA indices in image cytometry (Nagel & Al-Abadi, 1991).
In the present FCM analysis only 4% of the tumours showed
intra-tumour variability in DI, and the mean variation of
SPF within a tumour was also low. Accordingly, the results
suggest that intra-tumour heterogeneity of DNA ploidy and
SPF is a rare phenomenon in prostatic adenocarcinoma, in
contrast to several other epithelial neoplasms (Kallioniemi,
1988; Carey et al., 1990; Fern6 et al., 1992; Lipponen et al.,
1993). When interpreting the results of heterogeneity analysis
one should note that the sampling of tissue was not com-
pletely random, which may skew the results. However, the
results give a good estimate of the overall reproducibility of
the DNA measurements in this cohort of patients. Com-
parative studies between different laboratories have shown
that ploidy classifications may vary in 10-15% of tumours
when the measurements are taken from adjacent tissue sec-
tions in prostatic carcinoma (FossA et al., 1992). However, it
cannot be excluded that part of this variation has a
biological basis since tumours are often highly heterogenous
in their cellular features.
DNA aneuploidy was related to invasive high-grade
disease, which is in agreement with previous reports in pros-
tatic adenocarcinoma (Jones et al., 1990; Eskelinen et al.,
1991; Tribukait, 1991; Visakorpi et al., 1991; Di Silvero et
al., 1992). The present results confirm previous observations
in that tetraploidy is related to intermediate or high stages
(Eskelinen et al., 1991; Tnrbukait, 1991), while the fraction of
tumours with multiple cell lines was clearly lower than in
some previous reports (Tribukait, 1991). However, there was
no difference in the prognostic value between various levels
of aneuploidy, as reported by some investigators (Hedlund et
al., 1988; Tribukait, 1991). The present results are in accord
with the results in other epithelial carcinomas (Frierson,
1991; Lipponen et al., 1993). in which the degree of aneu-
ploidy as measured by flow cytometry had no additional
prognostic value.
The SPF values were similar in Tru-cut biopsy specimens
and in surgical or transurethral resection specimens, and
accordingly the type of specimen was not a significant con-
founding factor, although Fassa et al. (1992) reported some
differences in FCM results in different types of biopsy.
Aneuploid tumours showed significantly higher SPF values
than the diploid tumours, which is in accord with previous
results (Eskelinen et al., 1991; Visakorpi et al., 1991). The
degree of aneuploidy had little influence on SPF value, which
further supports the limited prognostic value of the degree of
aneuploidy. In addition, the clinical correlations in this
analysis and in previous reports (Eskelinen et al., 1991;
Visakorpi et al., 1991) suggest that the SPF is a more impor-
tant prognostic indicator than ploidy. In other epithelial
tumours, the proliferation rate of cancer cells has been
included, in addition to clinical stage, among the independent
predictors (Frierson, 1991; Lipponen et al., 1993). The pro-
liferation of cells is regulated through specific genes
(Visakorpi et al., 1992), and aneuploidy may be a reflection
of genetic instability rather than proliferative potential.
Histopathological grading has been shown to correlate
with stage and prognosis in prostatic adenocarcinoma
(Mostofi, 1975; Gleason, 1977; Oesterling et al., 1987;
Badalament et al., 1991; Visakorpi et al., 1991). However,
tumours with intermediate differentiation are biologically
heterogeneous (Nagel & Al-Abadi, 1991), and accordingly
the prognosis of patients with these tumours is also variable.
In this analysis, tumours with Gleason scores 5-7 could be
regrouped into distinctly different prognostic groups by
FCM, which suggests a clinical application for FCM in
prostatic adenocarcinoma. The importance of this classifi-
cation could be confirmed in multivariate analysis, which
clearly showed that neither the original Gleason score nor
FCM data were included among the independent predictors.
Tumours with Gleason scores of 2-4 or 8-10 could not be
subdivided into prognostic groups by determining DI or
SPF, since nearly all the low-score tumours are diploid and
the high-score tumours aneuploid. This association is
reflected also in the results of analysis of T3-4 tumours,
which could not be regrouped. The combined use of quanti-
tative measurements and subjective histological assessment
has been previously tested in transitional cell bladder
tumours with similar results (Lipponen et al., 1992).
Although patient age and malignant histological features
(Gleason score, Di, SPF, clinical stage) were not significantly
interrelated, patient age was an independent prognostic fac-
tor in all T3-4 tumours. This suggests that compromised
general physical condition and reduced capacity to resist
tumour growth are of importance, as has been observed in
other neoplastic diseases (Aaltomaa et al., 1991). Most of the
previous survival analyses performed in prostatic carcinoma
have not considered age as a prognostic factor (Stephenson
et al., 1987; Badalament et al., 1991; Eskelinen et al., 1991;
Nagel & Al-Abadi, 1991; Tribukait, 1991; Di Silvero et al.,
1992; Peter-Gee et al., 1992), and accordingly the comparison
of results based on biological variables alone is difficult. The
year of treatment was included in the multivariate analysis
but did not relate to prognosis.
To test the possibility that the type of therapy might314 S. VESALAINEN et al.
influence the prognosis, therapy was included in separate
multivanate analyses, which showed that none of the
therapies improved the prognosis in relation to clinical, histo-
logical and FCM parameters. In contrast, hormonal therapy
was related to an unfavourable prognosis, which is probably
because of the preferential use of hormones in patients with
disseminated disease. Separate analyses of three major
therapy groups (hormones, electroresection, active surveil-
lance) showed that the same parameters had independent
prognostic significance as in the entire cohort. Accordingly,
the results of these analyses suggest that the biological char-
acteristics of prostatic tumours are most important for the
outcome of the patients.
In summary, we conclude that DNA aneuploidy and a
high SPF are related to a malignant phenotype in prostatic
adenocarcinomas. In practice, FCM can be used to subdivide
tumours with Gleason scores of 5-7 into subgroups with
different prognoses. The combination of FCM, conventional
histological grading and clinical or histological staging pro-
vides accurate prognostic information in prostatic adenocar-
cinomas.
This study was supported by a grant from Savo Cancer Fund. The
technical assistance of Ms Monica Schoultz is gratefully ack-
nowledged.
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